 | You can helpexpand this article with text translated fromthe corresponding article in German. (September 2019)Click [show] for important translation instructions.
|
 | |
| Company type | Private |
|---|---|
| Industry | Pharmaceutical industry |
| Founded | 1890 |
| Headquarters | |
Key people | Luca Lastrucci (Chairman of the Executive Board) Edward Szybowski Christian Matschke Attilio Sebastio Christiane von der Eltz Ivan Bergstein |
| Revenue | 1.5 billionEUR (2021)[1] |
| Owner | Menarini Group |
Number of employees | 5,000 (2021)[1] |
| Website | www.berlin-chemie.com |
Berlin-Chemie Menarini is aGerman-Italian pharmaceutical company based inBerlin, Germany, andFlorence, Italy. The company was formed in1992 by the merger of theGerman company Berlin-Chemie andItalian companyMenarini.
Berlin-Chemie considers the establishment of a plant for the laboratory preparations of the Chemical factory of Kahlbaum in Berlin-Adlershof in 1890, as its origin.[2] The first factory located in the former administrative district ofTreptow, Berlin-Adlershof.[3] In 1927 after the merger withSchering AG employees began the development of drugs. After the end of the Second World War, the Adlershof factory of Schering AG was located in the Soviet occupation zone and thus in the later German Democratic Republic. From the mid-50s onwards, the company signed as VEB Berlin-Chemie. When the state-owned companies were privatized or dissolved after the political turnaround, the Italian group Menarini took over the factory in Berlin in 1992, including the product name, and thus immediately found a larger sales market in Eastern Europe.[4]
In February 2013, Berlin-Chemie took over the Priligy brand, a drug against premature ejaculation. Since mid-2013, there has been a media campaign on the internet and through posters on the subject of premature ejaculation, which many physicians are critical of. According to the imprint of the website in question, Later Come.de, this is a media contribution by Berlin-Chemie AG.[5]
Since 2015, Berlin-Chemie has been able to manufacture and sell anti-cancer drugs through a license agreement with the Japanese drug manufacturerChugai.[6]
The production of infusion solutions was discontinued in 2019.
In 2023, theWorld Intellectual Property Organization (WIPO)’s Madrid Yearly Review ranked Berlin Chemie's number of marks applications filled under theMadrid System as 6th in the world, with 107trademarks applications submitted during 2023.[7]
| International | |
|---|---|
| National | |
 | This German corporation or company article is astub. You can help Wikipedia byexpanding it. |
